TY - JOUR T1 - Risk Benefit of FOLFIRI Plus Ramucirumab as Third-line and Later-line Treatment of Metastatic Colorectal Cancer JF - Anticancer Research JO - Anticancer Res SP - 1605 LP - 1611 DO - 10.21873/anticanres.14108 VL - 40 IS - 3 AU - MICHIO KIMURA AU - EISEKI USAMI AU - HITOMI TERAMACHI AU - TOMOAKI YOSHIMURA Y1 - 2020/03/01 UR - http://ar.iiarjournals.org/content/40/3/1605.abstract N2 - Background/Aim: The aim of this study was to clarify the risk benefits of folinic acid, fluorouracil, and irinotecan (FOLFIRI) plus ramucirumab (F-RAM) as third-line and later-line treatment for metastatic colorectal cancer (mCRC). Patients and Methods: We compared the overall survival (OS), adverse events (AEs), and cost of F-RAM to those of trifluridine/tipiracil combination tablet (TAS-102). Results: There was no significant difference in the median OS [6.1 (range=1.2-16.3) months vs. 6.1 (range=1.2-22.3) months; log-rank test, p=0.272] and treatment duration [4.0 (range=1.2-9.6) months vs. 3.5 (range=0.2-12.3) months, p=0.888] between the F-RAM (n=13) and the TAS-102 (n=36) groups. However, AEs were more frequent in the F-RAM group, and 1-year administration of F-RAM cost higher ($81,724.8 vs. $18,931.4, p<0.001). Conclusion: F-RAM as third-line and later-line treatment for mCRC has a poor risk benefit. TAS-102 should be given priority over F-RAM. ER -